Articles

Economic burden of patients with leading cancers in China: a cost-of-illness study

Ziting Wu , Yiwen Yu, Feng Xie, et al. BMC Health Serv Res. 2024 Sep 27;24(1): 1135

China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China. This cross-sectional cost-of-illness study analyze... Read More

15 Apr, 2026

A Systematic Review of The Economic Burden of Colorectal Cancer

Aug.Abdosaleh Jafari, Fatemeh A Hosseini, Faride S Jalali et al. Health Sci Rep. 2024 Aug 21;7(8):e70002

Colorectal cancer is the third most common cancer in the Western Hemisphere. It is the third most common cancer in men after prostate and lung cancers and the second most common cancer in women after breast cancer. According to some studies, the incidence and prevalence of colorectal cancer is increasing rapidly. ... Read More

15 Apr, 2026

Estimated Out-of-Pocket Costs for Patients with Common Cancers and Private Insurance

Liam Rose, Ganesh Rajasekar , Anjali Nambiar , et al. JAMA Netw Open. 2025 Jul 1;8(7):e2521575

Cancer imposes a substantial economic burden on patients that may be worse in patients with higher-stage disease due to the need for more therapy. This retrospective cohort study used administrative claims data of a large national insurer in the US. The cohort consisted of 46,158 patients age at diagnosis, 46 years; 30... Read More

15 Apr, 2026

Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe

Agnes Brandtmüller , Anne Meiwald , Peter Toth , et al. J Med Econ 2026 Dec;29(1):785-798

Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types with the highest morbidity burden across 28 European countries in 2022. Tracheal, bronchus, and lung cancer, col... Read More

15 Apr, 2026

Projected Impact on Labor Productivity Costs of Cancer Related Premature Mortality in Europe 2018–2040

Marta Ortega Ortega, Paul Hanly, Alison Pearce, et al. Applied Health Economics and Health Policy (2023) 21:877–889

Between 2018 and 2040, cancer is expected to cause around eight million premature deaths (58% male). The cumulative projected productivity costs in this respect are €1.3 trillion, representing an annual average of €58.7 billion, or 0.43% of the EU-27 gross domestic product. Labour productivity costs are projected to de... Read More

15 Apr, 2026

Prevent Cancer 2026 Survey

Cost concerns now rival fear of cancer diagnosis, new survey findsFindings from the Prevent Cancer Foundation’s 2026 Early Detection Survey reveal that concern about unexpected costs of getting routine cancer screenings now rivals the fear of getting diagnosed with cancer. More than one in three U.S. adults (34%) who w... Read More

09 Apr, 2026

Prevent Cancer Survey 2025

According to the Prevent Cancer Foundation’s 2025 Early Detection Survey, just 51% of U.S. adults 21 years of age and older say they have had a routine medical appointment or routine cancer screening in the last year.1  This is a 10-percentage point drop from the 2024 survey.The survey did reveal some encoura... Read More

06 Apr, 2026

Routine cancer screening and medical appointment behaviors

There’s been a change in how often U.S. adults are going to routine medical appointments and cancer screenings, and according to the Prevent Cancer Foundation’s 2025 Early Detection Survey, we’re moving in the wrong direction.The survey revealed just 51% of U.S. adults 21 years of age and older say they have had a... Read More

06 Apr, 2026

Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence

Darren R. Brenner; Yibing Ruan; Chantelle Carbonell. JAMA Network Open. 2025;8(9):e2530904

Excess body size has emerged as an impactful component of population-level cancer risk. Current data suggest that at least 13 cancer sites are convincingly associated with excess body size, most often characterized by a body mass index (BMI) greater than 25.0. These results have been impressive, especially when compar... Read More

24 Mar, 2026

Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study

Xianhua Mao, Xinrong Zhang, Linda Henry, et al. JNCI: J. National Cancer Institute, 117:10, October 2025, 2053-2061

Among 919, 609 overweight or obese individuals with type 2 diabetes, 16 653 newly diagnosed with obesity-related cancer were recorded during the 2, 086 ,526 person-years of follow-up. GLP-1 agonist users (vs other glucose-lowering drugs users) were associated with lower incidence and risk of obesity-related cancer. Thi... Read More

24 Mar, 2026